We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

By LabMedica International staff writers
Posted on 10 Jan 2025
Print article
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company Innovaccer Inc. (San Francisco, CA, USA) with the aim of improving patient outcomes and experience through novel digital and diagnostic solutions. The investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

Innovaccer has developed a suite of software solutions designed to create a unified patient record to identify gaps in care and patients at risk, as well as appropriate interventions to improve patient outcomes. As part of the investment partnership, Danaher, along with Innovaccer and its network of healthcare systems, aims to accelerate the adoption of precision diagnostics both by clinicians and population health teams, facilitating value-based care.

"Patients are at the center of everything we do at Danaher. We believe our investment partnership with Innovaccer will empower patients and speed the transition to more personalized, value-based medicine by providing healthcare providers with the data and analytics needed to drive meaningful clinical insights, more quickly, and at the point of need," said Julie Sawyer Montgomery, Executive Vice President, Danaher Corporation.

"Danaher is committed to ethically using AI to develop and deliver better diagnostics to help doctors treat their patients with the right medicine in the right dose at the right time," said Murali Venkatesan, Head of Danaher Ventures, Americas & Europe and Vice President of Science, Technology and Innovation, Danaher Corporation. "We're excited to connect our innovation ecosystem with Innovaccer's to enable this healthcare transformation."

"At Innovaccer, we are on a mission to improve health outcomes through our data platform and AI capabilities," said Abhinav Shashank, cofounder and CEO of Innovaccer. "We believe that partnering with Danaher will accelerate our efforts to advance diagnostic and clinical AI solutions."

Related Links:
Danaher Corporation
Innovaccer Inc.

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.